Download Metabolic Disorders - Pipeline Review, H1 2013 Brochure

Brochure
More information from http://www.researchandmarkets.com/reports/2508209/
Metabolic Disorders - Pipeline Review, H1 2013
Description:
Metabolic Disorders – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, 'Metabolic Disorders - Pipeline Review, H1 2013', provides an overview of the
indication’s therapeutic pipeline. This report provides information on the therapeutic development for
Metabolic Disorders, complete with latest updates, and special features on late-stage and discontinued
projects. It also reviews key players involved in the therapeutic development for Metabolic Disorders.
Metabolic Disorders - Pipeline Review, Half Year is built using data and information sourced from Global
Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations
and featured press releases from company/university sites and industry-specific third party sources, put
together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of
data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Metabolic Disorders.
- A review of the Metabolic Disorders products under development by companies and universities/research
institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration
stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Metabolic Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Metabolic
Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies
to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Metabolic Disorders pipeline depth and
focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the
most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that
drove them from pipeline.
Contents:
2
List of Tables 6
List of Figures 8
Introduction 9
REPORT COVERAGE 9
Metabolic Disorders Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Metabolic Disorders 11
Metabolic Disorders Therapeutics under Development by Companies 13
Metabolic Disorders Therapeutics under Investigation by Universities/Institutes 19
Late Stage Products 20
Comparative Analysis 20
Mid Clinical Stage Products 21
Comparative Analysis 21
Early Clinical Stage Products 22
Comparative Analysis 22
Discovery and Pre-Clinical Stage Products 23
Comparative Analysis 23
Metabolic Disorders Therapeutics – Products under Development by Companies 24
Metabolic Disorders Therapeutics – Products under Investigation by Universities/Institutes 29
Companies Involved in Metabolic Disorders Therapeutics Development 30
Bristol-Myers Squibb Company 30
Athersys, Inc. 31
Genentech, Inc. 32
Daiichi Sankyo Company, Ltd 33
Merck & Co., Inc. 34
Takeda Pharmaceutical Company Limited 35
Ipsen S.A. 36
Glenmark Pharmaceuticals Ltd. 37
Genfit 38
Arrowhead Research Corporation 39
Ore Pharmaceuticals Inc 40
Corcept Therapeutics Incorporated 41
Alexion Pharmaceuticals, Inc. 42
CSL Limited 43
Regeneron Pharmaceuticals, Inc. 44
Unigene Laboratories, Inc. 45
XOMA Ltd. 46
Torrent Pharmaceuticals Limited 47
Suven Life Sciences Ltd. 48
Debiopharm Group 49
StemCells, Inc. 50
Axxam SpA 51
Camurus AB 52
Sirtris Pharmaceuticals, Inc. 53
Acceleron Pharma, Inc. 54
Helsinn Healthcare S.A. 55
Wellstat Therapeutics Corporation 56
Xenon Pharmaceuticals Inc. 57
Affibody AB 58
Ascent Therapeutics 59
Zafgen Inc. 60
Trevena, Inc. 61
Tranzyme Pharma, Inc. 62
Zealand Pharma A/S 63
Synageva BioPharma Corp. 64
Omeros Corporation 65
Obio Pharmaceutical Holdings Limited. 66
ChemoCentryx, Inc. 67
Vitae Pharmaceuticals, Inc. 68
Limerick BioPharma, Inc. 69
Lipopharma 70
Pharis Biotec GmbH 71
Relypsa, Inc. 72
Regulus Therapeutics Inc. 73
Esperion Therapeutics, Inc. 74
aTyr Pharma, Inc. 75
Heptares Therapeutics Ltd. 76
Envoy Therapeutics, Inc. 77
Zacharon Pharmaceuticals, Inc. 78
Galmed International Ltd. 79
Faron Pharmaceuticals, Ltd. 80
Progenra, Inc. 81
Metabolic Disorders – Therapeutics Assessment 82
Assessment by Monotherapy Products 82
Assessment by Route of Administration 83
Assessment by Molecule Type 85
Drug Profiles 87
Glucose-Dependent Insulinotropic Peptide - Drug Profile 87
Debio-0930 - Drug Profile 88
G-15750 - Drug Profile 89
TGFTX-1 Program - Drug Profile 90
TGFTX-3 Program - Drug Profile 91
TZP-301 - Drug Profile 92
romazarit - Drug Profile 93
Human Liver Engrafting Cells - Drug Profile 94
Stearoyl-CoA Desaturase-1 Drug Development Program - Drug Profile 96
ETC-1002 - Drug Profile 97
P-2202 - Drug Profile 99
P-7435 - Drug Profile 101
P-1201 - Drug Profile 102
Selective GR-II Receptor Antagonist - Drug Profile 103
Aramchol - Drug Profile 104
Ganglioside Inhibitor Program - Drug Profile 106
RNAi Therapeutics Program - Drug Profile 107
KP-9928 - Drug Profile 108
LIM-0723 - Drug Profile 109
ACE-435 - Drug Profile 110
MTP-131 - Drug Profile 111
GRC-9332 - Drug Profile 113
bezafibrate - Drug Profile 114
citrulline - Drug Profile 115
uridine triacetate - Drug Profile 116
recombinant human Zinc-a2-glycoprotein - Drug Profile 118
T2 Mimetic - Drug Profile 119
SBC-105 - Drug Profile 120
CORT-113083 - Drug Profile 121
RLY-106 - Drug Profile 122
IGF-1 Analogue - Drug Profile 123
LP-205A1 - Drug Profile 124
Ghrelin Receptor Antagonists - Drug Profile 125
Anti microRNA-33a/b - Drug Profile 126
SRT-3025 - Drug Profile 128
Drug For Metabolic Disorders - Drug Profile 130
Drug For Metabolic Disorders - Drug Profile 131
LP-30171 - Drug Profile 132
UX-007 - Drug Profile 133
SUVN-504 - Drug Profile 134
Histamine-3 Antagonist - Drug Profile 135
Drug Acting On Nicotinic Acetylcholine Receptor Alpha-4 Beta-2 For Obesity And Metabolic Disorders - Drug
Profile 136
RG-7652 - Drug Profile 137
REGN-1033 - Drug Profile 138
Adipotide - Drug Profile 139
cPMP replacement therapy - Drug Profile 141
GPR120 Agonist - Drug Profile 142
Multiple Preclinical Programs - Drug Profile 143
Novel Peptide for Metabolic Diseases - Drug Profile 144
Second Generation Compounds - Drug Profile 145
CSL-346 - Drug Profile 146
Drug Targeting GPR50 - Drug Profile 147
Cardiometabolic Disease Program - Drug Profile 148
F-652 - Drug Profile 149
CCX-872 - Drug Profile 150
FP-1101/1102 - Drug Profile 151
Resectin Protein Based Drug - Drug Profile 152
Undisclosed Product For Metabolic Diseases - Drug Profile 153
Undisclosed Drug - Drug Profile 154
Program For Diabetes And Obesity - Drug Profile 155
11 Beta HSD-1 Inhibitor Program - Drug Profile 156
Drug Targeting IDOL - Drug Profile 158
Drugs Targeting Acetyl-CoA Carboxylase - Drug Profile 159
Compound-22e - Drug Profile 160
AM-251 - Drug Profile 161
xl-310 - Drug Profile 162
FGF21-Based Biologic - Drug Profile 164
Irisin - Drug Profile 165
Beta-Arrestin Biased GPCR Agonists - Drug Profile 166
Drug For Metabolic And Genetic Disorder - Drug Profile 167
Drug For Metabolic Disorders - Drug Profile 168
Metabolic Disorders Therapeutics – Drug Profile Updates 169
Metabolic Disorders Therapeutics – Discontinued Products 177
Metabolic Disorders Therapeutics - Dormant Products 178
Metabolic Disorders – Product Development Milestones 181
Featured News & Press Releases 181
Appendix 189
Methodology 189
Coverage 189
Secondary Research 189
Primary Research 189
Expert Panel Validation 189
Contact Us 190
Disclaimer 190
List of Tables
Number of Products Under Development for Metabolic Disorders, H1 2013 16
Products under Development for Metabolic Disorders – Comparative Analysis, H1 2013 17
Number of Products under Development by Companies, H1 2013 19
Number of Products under Development by Companies, H1 2013 (Contd..1) 20
Number of Products under Development by Companies, H1 2013 (Contd..2) 21
Number of Products under Development by Companies, H1 2013 (Contd..3) 22
Number of Products under Development by Companies, H1 2013 (Contd..4) 23
Number of Products under Investigation by Universities/Institutes, H1 2013 24
Comparative Analysis by Late Stage Development, H1 2013 25
Comparative Analysis by Mid Clinical Stage Development, H1 2013 26
Comparative Analysis by Early Clinical Stage Development, H1 2013 27
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 28
Products under Development by Companies, H1 2013 29
Products under Development by Companies, H1 2013 (Contd..1) 30
Products under Development by Companies, H1 2013 (Contd..2) 31
Products under Development by Companies, H1 2013 (Contd..3) 32
Products under Development by Companies, H1 2013 (Contd..4) 33
Products under Investigation by Universities/Institutes, H1 2013 34
Bristol-Myers Squibb Company, H1 2013 35
Athersys, Inc., H1 2013 36
Genentech, Inc., H1 2013 37
Daiichi Sankyo Company, Ltd, H1 2013 38
Merck & Co., Inc., H1 2013 39
Takeda Pharmaceutical Company Limited, H1 2013 40
Ipsen S.A., H1 2013 41
Glenmark Pharmaceuticals Ltd., H1 2013 42
Genfit, H1 2013 43
Arrowhead Research Corporation, H1 2013 44
Ore Pharmaceuticals Inc, H1 2013 45
Corcept Therapeutics Incorporated, H1 2013 46
Alexion Pharmaceuticals, Inc., H1 2013 47
CSL Limited, H1 2013 48
Regeneron Pharmaceuticals, Inc., H1 2013 49
Unigene Laboratories, Inc., H1 2013 50
XOMA Ltd., H1 2013 51
Torrent Pharmaceuticals Limited, H1 2013 52
Suven Life Sciences Ltd., H1 2013 53
Debiopharm Group, H1 2013 54
StemCells, Inc., H1 2013 55
Axxam SpA, H1 2013 56
Camurus AB, H1 2013 57
Sirtris Pharmaceuticals, Inc., H1 2013 58
Acceleron Pharma, Inc., H1 2013 59
Helsinn Healthcare S.A., H1 2013 60
Wellstat Therapeutics Corporation, H1 2013 61
Xenon Pharmaceuticals Inc., H1 2013 62
Affibody AB, H1 2013 63
Ascent Therapeutics, H1 2013 64
Zafgen Inc., H1 2013 65
Trevena, Inc., H1 2013 66
Tranzyme Pharma, Inc., H1 2013 67
Zealand Pharma A/S, H1 2013 68
Synageva BioPharma Corp., H1 2013 69
Omeros Corporation, H1 2013 70
Obio Pharmaceutical Holdings Limited., H1 2013 71
ChemoCentryx, Inc., H1 2013 72
Vitae Pharmaceuticals, Inc., H1 2013 73
Limerick BioPharma, Inc., H1 2013 74
Lipopharma, H1 2013 75
Pharis Biotec GmbH, H1 2013 76
Relypsa, Inc., H1 2013 77
Regulus Therapeutics Inc., H1 2013 78
Esperion Therapeutics, Inc., H1 2013 79
aTyr Pharma, Inc., H1 2013 80
Heptares Therapeutics Ltd., H1 2013 81
Envoy Therapeutics, Inc., H1 2013 82
Zacharon Pharmaceuticals, Inc., H1 2013 83
Galmed International Ltd., H1 2013 84
Faron Pharmaceuticals, Ltd., H1 2013 85
Progenra, Inc., H1 2013 86
Assessment by Monotherapy Products, H1 2013 87
Assessment by Stage and Route of Administration, H1 2013 89
Assessment by Stage and Molecule Type, H1 2013 91
Metabolic Disorders Therapeutics – Drug Profile Updates 174
Metabolic Disorders Therapeutics – Discontinued Products 182
Metabolic Disorders Therapeutics – Dormant Products 183
Metabolic Disorders Therapeutics – Dormant Products (Contd..1) 184
Metabolic Disorders Therapeutics – Dormant Products (Contd..2) 185
List of Figures
Number of Products under Development for Metabolic Disorders, H1 2013 16
Products under Development for Metabolic Disorders – Comparative Analysis, H1 2013 17
Products under Development by Companies, H1 2013 18
Products under Investigation by Universities/Institutes, H1 2013 24
Late Stage Products, H1 2013 25
Mid Clinical Stage Products, H1 2013 26
Early Clinical Stage Products, H1 2013 27
Discovery and Pre-Clinical Stage Products, H1 2013 28
Assessment by Monotherapy Products, H1 2013 87
Assessment by Route of Administration, H1 2013 88
Assessment by Stage and Route of Administration, H1 2013 89
Assessment by Molecule Type, H1 2013 90
Assessment by Stage and Molecule Type, H1 2013 91
Ordering:
Order Online - http://www.researchandmarkets.com/reports/2508209/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Page 1 of 2
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from
USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/
Order Information
Please verify that the product information is correct and select the format(s) you require.
Product Name:
Metabolic Disorders - Pipeline Review, H1 2013
Web Address:
http://www.researchandmarkets.com/reports/2508209/
Office Code:
SCHL3FA7
Product Formats
Please select the product formats and quantity you require:
Quantity
Electronic (PDF) Single User:
USD 2000
Electronic (PDF) Site License:
USD 4000
Electronic (PDF) Enterprisewide:
USD 6000
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title:
First Name:
Mr
Mrs
Dr
Miss
Last Name:
Email Address: *
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Ms
Prof
Page 2 of 2
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by credit card:
You will receive an email with a link to a secure webpage to enter your
credit card details.
Pay by check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.
Pay by wire transfer:
Please transfer funds to:
Account number
833 130 83
Sort code
98-53-30
Swift code
ULSBIE2D
IBAN number
IE78ULSB98533083313083
Bank Address
Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at
http://www.researchandmarkets.com/info/terms.asp
Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World